Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:50:33.177Z.
Calculation as of: 2026-10-06T15:50:33.177Z.
Quote observation: 2026-10-06T15:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$639.06M
Price/FCF Ratio
N/A
TTM Avg
3847.94
3Y Avg
3847.94
5Y Avg
3847.94
Market Cap
$669.48M
Price/FCF Ratio
16.50
TTM Avg
12.94
3Y Avg
32.63
5Y Avg
32.63
Market Cap
$676.98M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$610.48M
Price/FCF Ratio
1201.73
TTM Avg
742.47
3Y Avg
742.47
5Y Avg
415.90
Market Cap
$601.66M
Price/FCF Ratio
3.24
TTM Avg
7.03
3Y Avg
5.99
5Y Avg
6.65
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $643.89M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $646.58M | N/A | 697.87 | 748.88 | 748.88 |
| Climb Bio, Inc. (CLYM)vs › | $639.06M | N/A | 3847.94 | 3847.94 | 3847.94 |
| Prime Medicine, Inc. (PRME)vs › | $631.67M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.48M | 16.50 | 12.94 | 32.63 | 32.63 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $676.98M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $610.48M | 1201.73 | 742.47 | 742.47 | 415.90 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $610.36M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $601.66M | 3.24 | 7.03 | 5.99 | 6.65 |
| Helus Pharma Inc. (HELP)vs › | $684.30M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
